DE69928820D1 - Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten - Google Patents

Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten

Info

Publication number
DE69928820D1
DE69928820D1 DE69928820T DE69928820T DE69928820D1 DE 69928820 D1 DE69928820 D1 DE 69928820D1 DE 69928820 T DE69928820 T DE 69928820T DE 69928820 T DE69928820 T DE 69928820T DE 69928820 D1 DE69928820 D1 DE 69928820D1
Authority
DE
Germany
Prior art keywords
cardiomyocytes
survival
increase
compositions
act
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928820T
Other languages
English (en)
Inventor
Kenneth Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caritas St Elizabeth Medical Center of Boston
St Elizabeths Medical Center of Boston Inc
Original Assignee
Caritas St Elizabeth Medical Center of Boston
St Elizabeths Medical Center of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caritas St Elizabeth Medical Center of Boston, St Elizabeths Medical Center of Boston Inc filed Critical Caritas St Elizabeth Medical Center of Boston
Application granted granted Critical
Publication of DE69928820D1 publication Critical patent/DE69928820D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
DE69928820T 1998-10-02 1999-09-29 Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten Expired - Lifetime DE69928820D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10274098P 1998-10-02 1998-10-02
PCT/US1999/022633 WO2000020025A2 (en) 1998-10-02 1999-09-29 Akt compositions for enhancing survival of cells

Publications (1)

Publication Number Publication Date
DE69928820D1 true DE69928820D1 (de) 2006-01-12

Family

ID=22291457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928820T Expired - Lifetime DE69928820D1 (de) 1998-10-02 1999-09-29 Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten

Country Status (6)

Country Link
EP (1) EP1117426B1 (de)
JP (1) JP2002528390A (de)
AU (1) AU772731B2 (de)
CA (1) CA2335391A1 (de)
DE (1) DE69928820D1 (de)
WO (1) WO2000020025A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514305A (en) 1999-04-16 2004-01-30 Univ Yale eNOS mutations useful for gene therapy and therapeutic screening
NZ519087A (en) * 1999-11-23 2004-11-26 Regeneron Pharma Methods of inhibiting atrophy or promoting hypertrophy
US6689807B1 (en) * 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
US20040235163A1 (en) * 2001-08-22 2004-11-25 Mitsuhiro Yokota Myocardial cell apoptosis inhibitors
US20060294604A1 (en) * 2003-02-17 2006-12-28 Fridman Jordan S Model for studying the role of genes in tumor resistance to chemotherapy
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
WO2006023879A1 (en) * 2004-08-20 2006-03-02 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
US20090214507A1 (en) * 2004-08-20 2009-08-27 Regenerx Biopharmaceuticals, Inc. Method of treating preventing, inhibiting or reducing damage to cardiac tissue
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
CA2610265A1 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
BRPI0502497A (pt) * 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
WO2007100722A2 (en) * 2006-02-28 2007-09-07 Trustees Of Boston University Methods to identify factors associated with muscle growth and uses thereof
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2009091992A1 (en) * 2008-01-16 2009-07-23 Purdue Research Foundation Repairing damaged nervous system tissue with nanoparticles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
WO1994025621A1 (en) * 1993-04-30 1994-11-10 Lxr Biotechnology Inc. Methods of identifying potentially therapeutically effective agents and cell strains for use therein
AU9774698A (en) * 1997-09-09 1999-03-29 Regents Of The University Of California, The Inhibition of apoptotis using prosaposin receptor agonists

Also Published As

Publication number Publication date
CA2335391A1 (en) 2000-04-13
AU772731B2 (en) 2004-05-06
EP1117426B1 (de) 2005-12-07
WO2000020025A3 (en) 2000-07-06
JP2002528390A (ja) 2002-09-03
EP1117426A2 (de) 2001-07-25
AU6276399A (en) 2000-04-26
WO2000020025A9 (en) 2000-08-24
WO2000020025A2 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
DE69920935D1 (de) Vefahren zur verbesserung der süssefreigabe von sucralose
DE60029779D1 (de) Zusammensetzungen zur Herstellung von En-Thiol-Elastomeren
CY2006003I2 (el) Χρηση δαπτομυκινης
DE60238576D1 (de) Zusammensetzung zur Herstellung von Elektroden und Elektroden
WO2001044271A3 (en) Daptomycin analogs and their use as antibacterial agents
WO2001044272A3 (en) Daptomycin analogs as antibacterial agents
DE69923500D1 (de) Verfahren zur Herstellung von Fluorkautschukzusammensetzungen
DE69928820D1 (de) Akt zusammensetzungen zur steigerung des überlebens von kardiomyozyten
DE69328072D1 (de) Umweltfreundliche Zusammensetzungen zur Verbesserung des Viskositätsindexes
BG103914A (en) Maintained separation of delayed gels
ATE401309T1 (de) Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen
EP1423122A4 (de) Zusammensetzungen und verfahren in verbindung mit neuen benzodiazepin-verbindungen und ihre ziele
DE60100858D1 (de) Prozess zur herstellung der kristallinen form i von cabergolin
DE60008830D1 (de) Verfahren zur Herstellung von keramischen Zusammensetzungen
AU2002337388A1 (en) Improvements in or relating to inhibition of viruses
ATE303153T1 (de) Ibandroinsäure zur förderung der osseointegration der endoprothesen
DE60039965D1 (de) Zusammensetzung zur erwerbung von immunologischer toleranz
IL155360A0 (en) Processes for the isolation or purification of plavastatin and compositions containing plavastatin
DE69812438T2 (de) Zusammensetzung zur herstellung von brennstoff-briketts
DE60022565T2 (de) Verfahren zur Herstellung von Polyaminzusammensetzungen
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
GB9907516D0 (en) Improvements relating to the application of adhesive
IT1304593B1 (it) Composizione per combattere bio-organismi dannosi
GB0110097D0 (en) Improvements in or relating to the protection of live fish
DE60004725D1 (de) Verfahren zur Herstellung von Pigmentzusammensetzungen

Legal Events

Date Code Title Description
8332 No legal effect for de